RealFeedApp UniQure received FDA approval for AMT-130 gene therapy
The FDA accepted UniQure's marketing application for AMT-130 gene therapy targeting Huntington's disease, with an approval decision date set for May 1, 2027.
- Field
- gene therapy
- What they did
- Researchers tested how long the beneficial effects of psilocybin last in mice and found that these effects disappear quickly.
- Why it matters
- This is important for understanding how long one can expect benefits from psychedelics when treating depression or anxiety in humans.
#gene therapy#fda approval#uniqure#huntington's disease#amt-130
